Top

Prithviraj Bose, M.D.

Department of Leukemia, Division of Cancer Medicine

About Dr. Bose

After obtaining his medical degree in 2001 from the University of Calcutta in his hometown of Kolkata, India, where he attended the Calcutta Medical College, Dr. Bose began a residency in general medicine at the Institute of Post-Graduate Medical Education and Research in Kolkata, which he left in early 2004 to move to the United States. He then completed an internship in internal medicine at a University of Washington affiliate in Spokane, Washington in 2005, and residency at the Henry Ford Hospital in Detroit, Michigan in 2007, followed by a fellowship in hematology and oncology at the University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma from 2017 through 2010. Dr. Bose became American Board of Internal Medicine-certified in hematology and medical oncology in 2010.

He then went on to join the hematology/oncology faculty at Virginia Commonwealth University (VCU) in Richmond, VA, where he was an assistant professor of medicine and a member of the NCI-designated VCU Massey Cancer Center between July 2010 and January 2015. At VCU, Dr. Bose took care of patients with diverse hematologic malignancies and teamed up with noted translational scientist, Steven Grant, to design early phase clinical trials of novel, targeted drug combinations in AML.

In the Department of Leukemia at The University of Texas MD Anderson Cancer Center, which he joined in early 2015, Dr. Bose’s major clinical and research focus is on myeloproliferative neoplasms (MPNs). He works closely with Dr. Srdan Verstovsek, chief of the section of MPNs. The two have authored many articles together in peer-reviewed journals and books and continue to do so. Dr. Bose is also heavily involved in clinical trial design for patients with MPN, and also in other areas of MPN research. He is leading a number of important therapeutic clinical trials in myelofibrosis at MDACC, as well as in other MPNs such as essential thrombocythemia and systemic mastocytosis. He has presented his research at international conferences and regularly speaks on MPN topics. Dr. Bose’s other area of interest is chronic lymphocytic leukemia (CLL). His clinical practice consists largely of patients with MPNs or CLL, although he also treats many patients with MDS, CML and acute leukemias.

Dr. Bose sits on the MPN panel of the National Comprehensive Cancer Network. His work has appeared in leading peer-reviewed journals such as The New England Journal of Medicine, Blood, and Cancer Cell, as well as in Williams’ Hematology. Dr. Bose was previously editor-in-chief of Drug Target Insights, and is currently on the editorial board of Hematology. In 2011, Dr. Bose, then a first-year faculty member at Virginia Commonwealth University, was selected to participate in the American Society of Hematology’s prestigious Clinical Research Training Institute. Now a naturalized US citizen, Dr. Bose was granted permanent residence in the United States in 2013 in the select “outstanding researcher” (first preference) category.

Primary Appointment

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2001	Calcutta Medical College, University of Calcutta, Kolkata, IND, MBBS, Medicine

Postgraduate Training

2007-2010	Clinical Fellowship, Hematology/Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
2005-2007	Clinical Residency, Internal Medicine, Henry Ford Hospital, Detroit, MI
2004-2005	Clinical Internship, Internal Medicine, Internal Medicine Residency Spokane, Spokane, WA

Honors & Awards

2011	Physician's Recognition Award with Commendation, American Medical Association
2011	Clinical Research Training Institute, American Society of Hematology

Selected Publications

Peer-Reviewed Articles

Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol 187(1):e1-e4, 2019. e-Pub 2019. PMID: 31344256.
Gotlib J, Baird JH, George TI, Langford C, Reyes I, Abuel J, Perkins C, Schroeder K, Bose P, Verstovsek S. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. Blood Adv 3(15):2264-2271, 2019. PMID: 31350306.
Gordon SW, McGuire WP, Shafer DA, Sterling RK, Lee HM, Matherly SC, Roberts JD, Bose P, Tombes MB, Shrader EE, Ryan AA, Kmieciak M, Nguyen T, Deng X, Bandyopadhyay D, Dent P, Poklepovic AS. Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. Am J Clin Oncol 42(8):649-654, 2019. PMID: 31305287.
Masarova L, Bose P, Verstovsek S. The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Curr Hematol Malig Rep 14(4):310-327, 2019. PMID: 31228096.
Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma 60(7):1767-1774, 2019. e-Pub 2019. PMID: 30632841.
Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia 33(6):1373-1386, 2019. e-Pub 2018. PMID: 30575820.
Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852-864, 2019. e-Pub 2019. PMID: 30924136.
Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer 125(11):1855-1866, 2019. e-Pub 2019. PMID: 30811597.
Bose P, Verstovsek S. MF Management. Hemasphere 3(suppl 2):149-152, 2019. e-Pub 2019.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. PMID: 31141631.
Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 19(3):142-148.e1, 2019. e-Pub 2018. PMID: 30635233.
Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol 94(1):74-79, 2019. e-Pub 2018. PMID: 30328139.
Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2018. PMID: 30545576.
Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN. Superior efficacy of co-treatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J 9(2):4, 2019. e-Pub 2019. PMID: 30647404.
Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podoltsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Wadleigh M, Walsh K, Bergman MA, Sundar H. Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16(12):1500-1537, 2018. PMID: 30545997.
Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Mutational landscape of myelodysplastic/myeloproliferative neoplasm - unclassifiable (MDS/MPN-U). Blood 132(19):2100-3, 2018. e-Pub 2018. PMID: 30242087.
Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood 132(21):2249-2259, 2018. e-Pub 2018. PMID: 30254130.
Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Grant S, Holkova B. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk 18(9):569-575.e1, 2018. e-Pub 2018. PMID: 30122201.
Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov Z. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol 97(7):1183-1191, 2018. e-Pub 2018. PMID: 29557496.
Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 124(13):2740-2747, 2018. e-Pub 2018. PMID: 29723397.
Bose P, Swaminathan M. JAK inhibition and symptom control in myeloproliferative neoplasms. Curr Med Res Opin 34(5):1-6, 2018. e-Pub 2018. PMID: 29415577.
Masarova L, Alhuraiji A, Bose P, Daver N, Pemmaraju N, Cortes J, Pierce S, Kantarjian H, Verstovsek S. Significance of thrombocytopenia in patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol 100(3):257-263, 2018. e-Pub 2018. PMID: 29226426.
Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A phase II trial of Ruxolitinib in combination with Azacytidine in Myelodysplastic Syndrome/Myeloproliferative Neoplasms. Am J Hematol 93(2):277-285, 2018. e-Pub 2017. PMID: 29134664.
Alhuraiji A, Naqvi K, Huh YO, Ho C, Verstovsek S, Bose P. Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure. Clin Case Rep 6(1):155-611, 2018. e-Pub 2017. PMID: 29375856.
Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour EJ, Konopleva M, Garcia-Manero G, Cortes J, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia 32(1):241-244, 2018. PMID: 28919634.
Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol 93(1):91-99, 2018. e-Pub 2017. PMID: 29047158.
Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol 8:369, 2018. e-Pub 2018. PMID: 30319961.
Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma 58(9):1-17, 2017. e-Pub 2017. PMID: 28140720.
Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res 59:110-116, 2017. e-Pub 2017. PMID: 28601551.
Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clonal Evolution and Outcomes in Myelofibrosis After Ruxolitinib Discontinuation. Blood 130(9):1125-31, 2017. e-Pub 2017. PMID: 28674026.
Boddu P, Falchi L, Hosing C, Newberry K, Bose P, Verstovsek S. The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review. Leuk Res 58:14-22, 2017. e-Pub 2017. PMID: 28380402.
Bose P, Verstovsek S. JAK2 inhibitors for myeloproliferative neoplasms: what is next?. Blood 130(2):115-125, 2017. e-Pub 2017. PMID: 28500170.
Holkova B, Yazbeck V, Kmieciak M, Bose P, Ma S, Kimball A, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Singh A, Hogan KT, Conine S, Sankala H, Roberts JD, Shea TC, Grant S. A Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma. Leuk Lymphoma 58(6):1349-1357, 2017. e-Pub 2017. PMID: 28103725.
Strati P, Masarova L, Bose P, Daver N, Pemmaraju N, Verstovsek S. Haptoglobin is Frequently Low in Patients with Myelofibrosis: Clinical Relevance. Leuk Res 57:85-88, 2017. e-Pub 2017. PMID: 28324773.
Abou Zahr A, Bose P, Keating MJ. Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. Expert Opin Pharmacother 18(9):857-873, 2017. e-Pub 2017. PMID: 28446054.
Bose P, Abou Zahr A, Verstovsek S. Investigational Janus Kinase inhibitors in development for myelofibrosis. Expert Opin Investig Drugs 26(6):723-734, 2017. e-Pub 2017. PMID: 28441920.
Strati P, Bose P, Lyle L, Gaw K, Zhou L, Pierce SA, Huynh-Lu J, Hirsch-Ginsberg CF, Bueso-Mendoza DE, Bueso-Ramos CE, Verstovsek S. Novel Hematological Parameters for the Evaluation of Patients with Myeloproliferative Neoplasms: the Immature Platelet and Reticulocyte Fractions. Ann Hematol 96(5):733-738, 2017. e-Pub 2017. PMID: 28247057.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res 15(5):610-618, 2017. e-Pub 2017. PMID: 28130399.
Naqvi K, Daver N, Pemmaraju N, Bose P, Garcia-Manero G, Cortes J, Kantarjian HM, Verstovsek S. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leuk Lymphoma 58(4):1-6, 2017. e-Pub 2016. PMID: 27494751.
Falchi L, Bose P, Newberry KJ, Verstovsek S. Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?. Br J Haematol 176(3):352-364, 2017. e-Pub 2016. PMID: 27984634.
Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol 4(2):e67-e74, 2017. e-Pub 2017. PMID: 28089238.
Bose P, Gandhi V. Recent therapeutic advances in chronic lymphocytic leukemia. F1000Res 6:1924, 2017. e-Pub 2017. PMID: 29152232.
Bose P, Verstovsek S. Investigational histone dea¬cetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opin Investig Drugs 25(12):1393-1403, 2016. e-Pub 2016. PMID: 27756180.
Bose P, Verstovsek S. Myelofibrosis: An Update on Drug Therapy in 2016. Expert Opin Pharmacother 17(18):2375-2389, 2016. e-Pub 2016. PMID: 27774820.
Bose P, Verstovsek S. Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management. J Natl Compr Canc Netw 14(12):1613-1624, 2016. PMID: 27956543.
Cervantes-Gomez F, Kumar Patel V, Bose P, Keating MJ, Gandhi V. Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes. Leukemia 30(8):1803-4, 2016. PMID: 27198052.
Poklepovic A, Gordon S, Shafer DA, Roberts JD, Bose P, Geyer CE, McGuire WP, Tombes MB, Shrader E, Strickler K, Quigley M, Wan W, Kmieciak M, Massey HD, Booth L, Moran RG, Dent P. Phase I study of pemetrexed with sorafenib in advanced solid tumors. Oncotarget 7(27):42625-42638, 2016. e-Pub 2016. PMID: 27213589.
Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan D, Landgren O, Grant S. A Phase 2 Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res 22(5):1067-75, 2016. e-Pub 2015. PMID: 26446942.
Bose P, Verstovsek S. The evolution and clinical relevance of prognostic classification systems in myelofibrosis. Cancer 122(5):681-92, 2016. e-Pub 2015. PMID: 26717494.
Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, Feng C, Peterson DR, Fisher RI, Grant S, Friedberg JW. Phase 1 Trial of Carfilzomib (PR-171) in Combination with Vorinostat (SAHA) in Patients with Relapsed or Refractory B-Cell Lymphomas. Leuk Lymphoma 57(3):1-30, 2016. e-Pub 2015. PMID: 26284612.
Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized Multicenter Phase 2 Study of Timed Sequential Therapy with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed Adult Acute Myeloid Leukemia (AML). Haematologica 100(9):172-179, 2015. e-Pub 2015. PMID: 26022709.
Dinnel J, Moore BL, Skiver BM, Bose P. Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy. Core Evid 10:23-38, 2015. e-Pub 2015. PMID: 25610345.
Vachhani P, Bose N, Brodeur JP, Holkova B, Bose P. Remission of rheumatoid arthritis on brentuximab vedotin. Rheumatology (Oxford) 53(12):2314-5, 2014. e-Pub 2014. PMID: 25239883.
Bose P, Batalo MS, Holkova B, Grant S. Bortezomib for the treatment of non-Hodgkin's lymphoma. Expert Opin Pharmacother 15(16):2443-59, 2014. e-Pub 2014. PMID: 25263936.
Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res 20(22):5652-62, 2014. e-Pub 2014. PMID: 25248382.
Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther 143(3):323-36, 2014. e-Pub 2014. PMID: 24769080.
Vachhani P, Bose P, Rahmani M, Grant S. Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML. Physiol Genomics 46(13):448-56, 2014. e-Pub 2014. PMID: 24824212.
Vachhani P, Bose P. Isolated gastric myeloid sarcoma: a case report and review of the literature. Case Rep Hematol 2014:541807, 2014. e-Pub 2014. PMID: 25105036.
Skiver BM, Patel SB, Bose P. It is not always immune thrombocytopenia: a case of MYH9-related platelet disorder caused by a novel mutation. Eur J Haematol 91(2):191-2, 2013. e-Pub 2013. PMID: 23489225.
Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs 22(6):723-38, 2013. e-Pub 2013. PMID: 23647051.
Bose P, Grant S. Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML). Leuk Res Rep 2(1):12-14, 2013. PMID: 23977453.
Bose P, Park H, Al-Khafaji J, Grant S. Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase. Leuk Res Rep 2(1):18-20, 2013. PMID: 23977454.
Bose P, Murugan P, Gillies E, Holter JL. Extraosseous Ewing's sarcoma of the pancreas. Int J Clin Oncol 17(4):399-406, 2012. e-Pub 2011. PMID: 21892669.
Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Douglas Figg W, Karp JE, Koc ON, Cooper BW, Luger SM, Colevas AD, Roberts JD, Grant S. Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. Cancer Chemother Pharmacol 69(6):1657-67, 2012. e-Pub 2012. PMID: 22349810.
Bose P, Parekh HD, Holter JL, Greenfield RA. Disseminated fusariosis occurring in two patients despite posaconazole prophylaxis. J Clin Microbiol 49(4):1674-5, 2011. e-Pub 2011. PMID: 21270218.
Bose P, Dunn ST, Yang J, Allen R, El-Khoury C, Tfayli A. c-Kit expression and mutations in phyllodes tumors of the breast. Anticancer Res 30(11):4731-6, 2010. PMID: 21115932.
Bose P, Ozer H. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Investig Drugs 18(11):1735-51, 2009. PMID: 19780706.
Bose P, Hussein KK, Terrell DR, Berger D, Rice L, George JN. Successful treatment of cyclic thrombocytopenia with thrombopoietin-mimetic agents: a report of two patients. Am J Hematol 84(7):459-61, 2009. PMID: 19484732.
Bose P, Thompson C, Gandhi D, Ghabach B, Ozer H. AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib. Eur J Haematol 82(6):490-2, 2009. e-Pub 2009. PMID: 19220417.
Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 360(20):2143-4, 2009. PMID: 19439755.
Bose P, Gandhi VV, Keating MJ. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opin Drug Metab Toxicol:1-12. e-Pub 2016. PMID: 27686109.
Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis. Blood. e-Pub 2018. PMID: 30185431.
Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7?+?3) in newly diagnosed high-risk acute myeloid leukemia (AML). Leuk Res 72:92-95. e-Pub 2018. PMID: 30118897.
Rausch CR, DiPippo AJ, Bose P, Kontoyiannis DP. Breakthrough fungal infections in leukemia patients receiving isavuconazole. Clin Infect Dis. e-Pub 2018. PMID: 29771293.
Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer. e-Pub 2019. PMID: 31310323.
Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica. e-Pub 2019. PMID: 31296578.
Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol. e-Pub 2019. PMID: 31243771.
Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol. e-Pub 2019. PMID: 31237017.
Mughal TI, Pemmaraju N, Radich JP, Deininger MW, Kucine N, Kiladjian JJ, Bose P, Gotlib J, Valent P, Chen CC, Barbui T, Rampal R, Verstovsek S, Koschmieder S, Saglio G, Van Etten RA. Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Hematol Oncol. e-Pub 2019. PMID: 31013548.

Invited Articles

Bose P, Alfayez M, Verstovsek S. New Concepts of Treatment for Patients with Myelofibrosis. Curr Treat Options Oncol 20(1):5, 2019. e-Pub 2019. PMID: 30675650.
Bose P, Verstovsek S. Accelerated Phase Myelofibrosis. Clin Lymphoma Myeloma Leuk 18(Suppl. 1):S40-S42, 2018.
Bose P, Verstovsek S. Management of myelofibrosis-related cytopenias. Curr Hematol Malig Rep 13(3):164-172, 2018. PMID: 29796726.
Bose P, Gotlib J, Harrison CN, Verstovsek S. SOHO State-of-the-art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk 18(1):1-12, 2018. PMID: 29277359.
Bose P. Myelofibrosis with cytopenias. Clin Lymphoma Myeloma Leuk 17(Suppl 2):S30-S31, 2017.
Bose P, Verstovsek S. Developmental Therapeutics in Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk 17S:S43-S52, 2017. PMID: 28760302.
Bose P, Vachhani P, Cortes JE. Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Curr Treat Options Oncol 18(3):17, 2017. e-Pub 2017. PMID: 28286924.
Bose P, Verstovsek S. Prognosis of Primary Myelofibrosis in the Genomic Era. Clin Lymphoma Myeloma Leuk 16 Suppl:S105-13, 2016. PMID: 27521306.
Bose P, Grant S. Rational combinations of targeted agents in AML. J Clin Med 4(4):634-664, 2015. e-Pub 2015. PMID: 26113989.
Bose P, Qubaiah O.. A review of tumor lysis syndrome with targeted therapies and the role of rasburicase. Journal of Clinical Pharmacy and Therapeutics 36(3):299-326, 2011. PMID: 21501203.

Editorials

Bose P, Chen LS, Gandhi V. Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'. Leuk Lymphoma 60(7):1603-1605, 2019. PMID: 30724681.
Bose P, Konopleva MY. ORY-1001: Overcoming the differentiation block in AML. Cancer Cell 33(3):342-343, 2018. PMID: 29533778.
Bose P, Konopleva MY. T-PLL: another check on the venetoclax list?. Blood 130(23):2447-2448, 2017. PMID: 29217697.
Bose P, Verstovsek S. Ruxolitinib for Essential Thrombocythemia?. Oncoscience 4(11-12):148-149, 2017. PMID: 29344542.
Bose P, Grant S. Orphan drug designation for pracinostat, volasertib and alvocidib in AML. Leuk Res 38(8):862-5, 2014. PMID: 24996975.
Bose P, Rahmani M, Grant S. Coordinate PI3K pathway and Bcl-2 family disruption in AML. Oncotarget 3(12):1499-500, 2012. PMID: 23439314.
Bose P, Grant S. Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia?. Expert Rev Hematol 5(5):475-8, 2012. PMID: 23146050.

Abstracts

Marina Kremyanskaya, Ronald Hoffman, John Mascarenhas, Prithviraj Bose, Vikas Gupta, Gary J. Schiller, Elena Liew, Claudia Lebedinsky, Adrian Mario Senderowicz, Jennifer Mertz, Patrick Trojer, Srdan Verstovsek. A phase II study of cpi-0610, a bromodomain and extraterminal protein inhibitor (BETi) alone or with ruxolitinib (RUX), in patients with myelofibrosis (MF). J Clin Oncol 37(suppl), 2019.
Abhishek Maiti, Farhad Ravandi, Jorge E. Cortes, Elias Jabbour, Kayleigh Marx, Naval Guastad Daver, Guillermo Garcia-Manero, Marina Konopleva, Christopher Brent Benton, Lucia Masarova, Courtney Denton Dinardo, Prithviraj Bose, Kiran Naqvi, Sherry A. Pierce, Hagop M. Kantarjian, Nicholas James Short. Venetoclax (VEN) and tyrosine kinase inhibitor (TKI) combinations in Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) and chronic myeloid leukemia myeloid blast phase (CML MBP). J Clin Oncol 37(suppl), 2019.
Kiran Naqvi, Elias Jabbour, Jeffrey A Skinner, Kristin N Anderson, Musa Yilmaz, Nitin Jain, Alessandra Ferrajoli, Prithviraj Bose, Philip A. Thompson, Yesid Alvarado, Koichi Takahashi, Jan Andreas Burger, Gautam Borthakur, Zeev Estrov, Naveen Pemmaraju, Shilpa Paul, Sara Dellasala, Jorge E. Cortes, Hagop M. Kantarjian. Update on lower-dose dasatinib 50 mg daily as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP). J Clin Oncol 37(suppl), 2019.
Prithviraj Bose, Naveen Pemmaraju, Naval Daver, Elias Jabbour, Sharon Bledsoe, Tapan Kadia, Zeev Estrov, Steven Kornblau, Gautam Borthakur, Lucia Masarova, Julie Huynh-Lu, Madeleine Henriquez, Mary Ann Richie, Jeannette Sun, Lingsha Zhou, Sherry Pierce, Xuemei Wang, Allison Pike, Hagop Kantarjian, Srdan Verstovsek. SOTATERCEPT (ACE-011) IN SUBJECTS WITH MPN-ASSOCIATED MYELOFIBROSIS AND ANEMIA. Hemasphere 3(suppl 1), 2019.
Prithviraj Bose, Srdan Verstovsek, Kiran Naqvi, Elias Jabbour, Courtney DiNardo, Yesid Alvarado, Naveen Pemmaraju, Naval Daver, Tapan Kadia, Nicholas Short, Nitin Jain, Christopher Benton, Koichi Takahashi, Zeev Estrov, Jorge Cortes, Graciela Nogueras-Gonzalez, Xuelin Huang, John Villareal, Sherry Pierce, Louis Wilson, Susan Tse, Hagop Kantarjian, Farhad Ravandi. PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML). Hemasphere 3(suppl 1), 2019.
Raajit Rampal, Srdan Verstovsek, Sean Devlin, Eytan Stein, Tapan Kadia, Michael Mauro, Naveen Pemmaraju, Guillermo Montalban-Bravo, Amber King, Kelsey Alvarez, Nicole Ard, Tawni Goodman, Bria Taylor, Prithviraj Bose. EARLY RESULTS OF A PHASE II STUDY OF COMBINED RUXOLITINIB AND THALIDOMIDE IN PATIENTS WITH MYELOFIBROSIS. Hemasphere 3(suppl 1), 2019.
Courtney DiNardo, Koichi Takahashi, Tapan Kadia, Sanam Loghavi, Kiran Naqvi, Prithviraj Bose, Naval Daver, George Donovan Tippett, Gautam Borthakur, Jorge Cortes, Steven Chan, Lynn Quek, Paresh Vyas, Hagop Kantarjian, Marina Konopleva. A PHASE 1B/2 CLINICAL STUDY OF TARGETED IDH1 INHIBITION WITH IVOSIDENIB, IN COMBINATION WITH THE BCL-2 INHIBITOR VENETOCLAX, FOR PATIENTS WITH IDH1-MUTATED (MIDH1) MYELOID MALIGNANCIES. Hemasphere 3(suppl 1), 2019.
Deepti Radia, Michael W. Deininger, Jason Gotlib, Prithviraj Bose, Mark W. Drummond, Elizabeth O. Hexner, William A. Robinson, Albert T. Quiery, Tracy I. George, Hans-Peter Horny, Ronny Oren, Hongliang Shi, Oleg Schmidt-Kittler, Brenton Mar, Daniel DeAngelo. AVAPRITINIB, A POTENT AND SELECTIVE INHIBITOR OF KIT D816V, INDUCES COMPLETE AND DURABLE RESPONSES IN PATIENTS (PTS) WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM). Hemasphere 3(suppl 1), 2019.
Ronald Hoffman, John Mascarenhas, Marina Kremyanskaya, Prithviraj Bose, Vikas Gupta, Gary Schiller, Elena Liew, Anna Godfrey, Jennifer Mertz, Jessica Piel, Patrick Trojer, Cludia Lebedinsky, Adrian Senderowicz, Sujan Kabir, Jeffrey Supko, Srdan Verstovsek. CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) INHIBITOR, REDUCES PRO-INFLAMMATORY CYTOKINES, BONE MARROW FIBROSIS AND THE NUMBER OF TRANSFUSIONS IN MYELOFIBROSIS PATIENTS. Hemasphere 3(suppl 1), 2019.
Kiran Naqvi, Elias Jabbour, Jeffrey Skinner, Kristin Anderson, Musa Yilmaz, Alessandra Ferrajoli, Prithviraj Bose, Philip Thompson, Yesid Alvarado, Nitin Jain, Koichi Takahashi, Jan Burger, Zeev Estrov, Gautam Borthakur, Naveen Pemmaraju, Sara Dellasala, Shilpa Paul, Jorge Cortes, Hagop Kantarjian. FOLLOW-UP OF LOWER DOSE DASATINIB 50MG DAILY AS FRONTLINE THERAPY IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP). Hemasphere 3(suppl 1), 2019.
Prithviraj Bose, David McCue, Nathan P. Wiederhold, Tapan M. Kadia, Gautam Borthakur, Farhad Ravandi, Musa Yilmaz, Koichi Takahashi, Philip A. Thompson, Naveen Pemmaraju, Naval G. Daver, Jan A. Burger, Jorge E. Cortes, Guillermo Garcia-Manero, Srdan Verstovsek, Marina Y. Konopleva, Nitin Jain, Courtney D. DiNardo, Yesid Alvarado, Kiran Naqvi, Steven M. Kornblau, Alessandra Ferrajoli, William G. Wierda, Zeev E. Estrov, Christopher B. Benton, Lucia Masarova, Guillermo Montalban-Bravo, Koji Sasaki, Caitlin R. Rausch, Kayleigh Marx, Wei Qiao, Xuelin Huang, Carol A. Bivins, Sherry A. Pierce, Hagop M. Kantarjian, Dimitrios P. Kontoyiannis. Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. Blood 132, 2018.
Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Zeev E. Estrov, Lingsha Zhou, Sherry A. Pierce, Jorge E. Cortes, Hagop M. Kantarjian, Srdan Verstovsek. Evaluation of Cytogenetic Stratifications in Myelofibrosis. Blood 132, 2018.
Raajit K. Rampal, Srdan Verstovsek, Sean M Devlin, Eytan M. Stein, Tapan M. Kadia, Michael J. Mauro, Naveen Pemmaraju, Kelsey Alvarez, Nicole Ard, Tawni Goodman, Kelly Marek, Prithviraj Bose. Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study. Blood 132, 2018.
Lucia Masarova, Srdan Verstovsek, Jorge E. Cortes, Naveen Pemmaraju, Prithviraj Bose, Maro N. Ohanian, Lingsha Zhou, Sherry A. Pierce, Romany Gergis, Gautam Borthakur, Zeev E. Estrov, Guillermo Garcia-Manero, Hagop M. Kantarjian and Naval G. Daver. Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis. Blood 132, 2018.
Uri Rozovski, Ping Li, David M. Harris, Zhiming Liu, Preetesh Jain, Alessandra Ferrajoli, Jan A. Burger, Prithviraj Bose, Philip A. Thompson, Nitin Jain, William G. Wierda, Michael J. Keating and Zeev E. Estrov. Endogenous STAT3-Activated Wnt5a Provides CLL Cells with Survival Advantage. Blood 132, 2018.
Fevzi Yalniz, Hagop M. Kantarjian, Gautam Borthakur, Tapan M. Kadia, Naval G. Daver, Naveen Pemmaraju, Marina Y. Konopleva, Guillermo Garcia-Manero, Koichi Takahashi, Courtney D. DiNardo, Prithviraj Bose, Michael Andreeff, Farhad Ravandi and Jorge E. Cortes. Potential Predictors of Induction Failure and Complete Remission Duration in FLT3-ITD Mutated Acute Myeloid Leukemia. Blood 132, 2018.
Uri Rozovski, David M. Harris, Ping Li, Zhiming Liu, Preetesh Jain, Alessandra Ferrajoli, Jan A. Burger, Prithviraj Bose, Philip A. Thompson, Nitin Jain, William G. Wierda, Michael J. Keating and Zeev E. Estrov. CLL Cells with 13q- Are Characterized By High BCL2 Levels and CLL Cells with Trisomy-12 By Increased Activation of STAT3 and NF-κB. Blood 132, 2018.
Fevzi Yalniz, Hagop M. Kantarjian, Tapan M. Kadia, Guillermo Garcia-Manero, Keyur Patel, Sanam Loghavi, Koji Sasaki, Naval G. Daver, Courtney D. DiNardo, Naveen Pemmaraju, Nicholas J Short, Musa Yilmaz, Prithviraj Bose, Kiran Naqvi, Sherry A. Pierce, Jorge E. Cortes and Farhad Ravandi. Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib. Blood 132, 2018.
Darwin Roman, Hagop M. Kantarjian, Jorge E. Cortes, Gautam Borthakur, Guillermo Garcia-Manero, Marina Y. Konopleva, Courtney D. DiNardo, Naval G. Daver, Naveen Pemmaraju, Tapan M. Kadia, Steven M. Kornblau, Prithviraj Bose, Michael Andreeff, Emil J. Freireich, Farhad Ravandi and Fleur M. Aung. Granulocyte Transfusions for Neutropenic Patients with Perirectal and Perineal Infections. Blood 132, 2018.
Jason R. Gotlib, Deepti Radia, Daniel J. DeAngelo, Prithviraj Bose, Mark W Drummond, Elizabeth O. Hexner, William A Robinson, Maureen G. Conlan, Ronny G. Oren, Hongliang Shi and Michael W. Deininger. Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM). Blood 132, 2018.
Mansour Alfayez, Hagop M. Kantarjian, Farhad Ravandi, Guillermo Garcia-Manero, Marina Y. Konopleva, Naval G. Daver, Courtney D. DiNardo, Gautam Borthakur, Prithviraj Bose, Michael Andreeff, Yesid Alvarado, Musa E. Yilmaz, Naveen Pemmaraju, Steven M. Kornblau, Zeev E. Estrov, Christopher B. Benton, Koichi Takahashi, Kiran Naqvi, Rebecca Slack, Rubiul Islam, Elias J. Jabbour, Jorge E. Cortes and Tapan M. Kadia. Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia. Blood 132, 2018.
Caitlin R. Rausch, Shilpa Paul, Guillermo Montalban Bravo, Elias J. Jabbour, Naval G. Daver, Yesid Alvarado, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Kiran Naqvi, Steven M. Kornblau, Jorge E. Cortes, Tapan M. Kadia, Marina Y. Konopleva, Maro N. Ohanian, Sherry A. Pierce, Yvonne Gasior, Christopher B. Benton, Nitin Jain, Koichi Takahashi, Lucia Masarova, Michael Andreeff, Zeev E. Estrov, Hagop M. Kantarjian and Guillermo Garcia-Manero. Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab. Blood 132, 2018.
Mansour Alfayez, Hagop M. Kantarjian, Nicholas J Short, Rita Assi, Maria Khouri, Farhad Ravandi, Shilpa Paul, Caitlin R. Rausch, Patrice Nasnas, Gautam Borthakur, Courtney D. DiNardo, Tapan M. Kadia, Naval G. Daver, Guillermo Garcia-Manero, Kiran Naqvi, Prithviraj Bose, Susan M. O'Brien, Jorge E. Cortes and Elias J. Jabbour. Safety and Efficacy of Blinatumomab in Patients with Central Nervous System (CNS) Disease: A Single Institution Experience. Blood 132, 2018.
Guillermo Garcia-Manero, Elias J. Jabbour, Marina Y. Konopleva, Naval G. Daver, Gautam Borthakur, Courtney D. DiNardo, Prithviraj Bose, Parita Patel, Rami S. Komrokji, Aditi Shastri, Gail J. Roboz, Robert Matthew Miller, Sarah Arbe-Barnes, Mary Reilly, Peter McGuirk, Tara Kearney, Brian Keogh and Hagop M. Kantarjian. A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy. Blood 132, 2018.
Guillaume Richard-Carpentier, Hagop M. Kantarjian, Farhad Ravandi, Tapan M. Kadia, Gautam Borthakur, Guillermo Garcia-Manero, Courtney D. DiNardo, William G. Wierda, Naval G. Daver, Naveen Pemmaraju, Prithviraj Bose, Marina Y. Konopleva, Michael Andreeff, Srdan Verstovsek, Heidi M Krause, Fleur M. Aung and Jorge E. Cortes. Safety and Efficacy of Non-Irradiated Granulocyte Transfusions (GTX) in Neutropenic Patients with Severe or Refractory Abdominal Infections: A Single Center Retrospective Analysis of 119 Transfusions in 22 Patients. Blood 132, 2018.
Eran Tallis, Hagop M. Kantarjian, Catherine Kendall Major, Maria Vazquez, Gautam Borthakur, Prithviraj Bose, Farhad Ravandi, Guillermo Garcia-Manero, Tapan M. Kadia, William G. Wierda, Alessandra Ferrajoli, Naveen Pemmaraju, Naval G. Daver, Courtney D. DiNardo, Marina Y. Konopleva, Steven M. Kornblau, Richard E Champlin, Elias J. Jabbour, Sherry A. Pierce and Jorge E. Cortes. Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Surviving More Than 5 Years (yrs) after Initial Therapy with TKIs. Blood 132, 2018.
Tapan M. Kadia, Marina Y. Konopleva, Guillermo Garcia-Manero, Christopher B. Benton, William G. Wierda, Prithviraj Bose, Musa E. Yilmaz, Elias J. Jabbour, Steven M. Kornblau, Kapil N. Bhalla, Naveen Pemmaraju, Nitin Jain, Rashmi Malla, Gautam Borthakur, Jorge E. Cortes, Farhad Ravandi and Hagop M. Kantarjian. Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias. Blood 132, 2018.
Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Koji Sasaki, Naval G. Daver, Elias J. Jabbour, Yesid Alvarado, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Kiran Naqvi, Jorge E. Cortes, Tapan M. Kadia, Marina Y. Konopleva, Caitlin R. Rausch, Yvonne Gasior and Hagop M. Kantarjian. Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). Blood 132, 2018.
Nitin Jain, Philip A. Thompson, Jan A. Burger, Alessandra Ferrajoli, Gautam Borthakur, Prithviraj Bose, Zeev E. Estrov, Tapan M. Kadia, Koichi Takahashi, Naveen Garg, Xuemei Wang, Rashmi Kanagal-Shamanna, Keyur Patel, Wanda Lopez, Ana Ayala, William Plunkett, Varsha Gandhi, Hagop M. Kantarjian, Susan M. O'Brien, Michael J Keating and William G. Wierda. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations. Blood 132, 2018.
Naveen Pemmaraju, Bing Z Carter, Hagop M. Kantarjian, Jorge E. Cortes, Tapan M. Kadia, Guillermo Garcia-Manero, Courtney D. DiNardo, Prithviraj Bose, Naval G. Daver, Marina Y. Konopleva, Maro N. Ohanian, Sherry A. Pierce, Lingsha Zhou, Zeev E. Estrov, Gautam Borthakur, Karina Salinas, Po Yee Mak, Nitin Jain, Elias J. Jabbour and Srdan Verstovsek. LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial. Blood 132, 2018.
Guillermo Garcia-Manero, Koji Sasaki, Guillermo Montalban-Bravo, Kristy R. Bodden, Prithviraj Bose, Yesid Alvarado, Naval G. Daver, Gautam Borthakur, Farhad Ravandi, Koichi Takahashi, Jorge E. Cortes, Elias J. Jabbour, Kiran Naqvi, Courtney D. DiNardo, Christopher B. Benton, Naveen Pemmaraju, Tapan M. Kadia, Maro N. Ohanian, Sherry A. Pierce and Hagop M. Kantarjian. Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS). Blood 132, 2018.
Nitin Jain, Michael J Keating, Philip A. Thompson, Alessandra Ferrajoli, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev E. Estrov, Nathan H. Fowler, Tapan M. Kadia, Marina Y. Konopleva, Yesid Alvarado, Musa Yilmaz, Courtney D. DiNardo, Prithviraj Bose, Maro N. Ohanian, Naveen Pemmaraju, Elias J. Jabbour, Koji Sasaki, Rashmi Kanagal-Shamanna, Keyur Patel, Jeffrey L. Jorgensen, Naveen Garg, Xuemei Wang, Katrina Sondermann, Nichole Cruz, Chongjuan Wei, Ana Ayala, William Plunkett, Hagop M. Kantarjian, Varsha Gandhi and William G. Wierda. Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL). Blood 132, 2018.
Nicholas J Short, Hagop M. Kantarjian, Sanam Loghavi, Xuelin Huang, Wei Qiao, Gautam Borthakur, Tapan M. Kadia, Naval G. Daver, Maro N. Ohanian, Courtney D. DiNardo, Zeev E. Estrov, Rashmi Kanagal-Shamanna, Abhishek Maiti, Christopher B. Benton, Prithviraj Bose, Yesid Alvarado, Elias J. Jabbour, Steven M. Kornblau, Naveen Pemmaraju, Nitin Jain, Yvonne Gasior, Mary Ann Richie, Sherry A. Pierce, Jorge E. Cortes, Marina Y. Konopleva, Guillermo Garcia-Manero and Farhad Ravandi. Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study. Blood 132, 2018.
Dyana T. Saenz, Warren Fiskus, Taghi Manshouri, David N Saenz, Raffaella Soldi, Baohua Sun, Christopher Peter Mill, Agnieszka J Nowak, Steven M. Kornblau, Prithviraj Bose, Tapan M. Kadia, Courtney D. DiNardo, Lucia Masarova, Steve Horrigan, Joseph David Khoury, Sunil Sharma, Srdan Verstovsek and Kapil N. Bhalla. Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis. Blood 132, 2018.
Guillermo Garcia-Manero, Koji Sasaki, Guillermo Montalban-Bravo, Naval G. Daver, Elias J. Jabbour, Yesid Alvarado, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Kiran Naqvi, Jorge E. Cortes, Tapan M. Kadia, Marina Y. Konopleva, Simona Colla, Hui Yang, Caitlin R. Rausch, Yvonne Gasior, Carlos E. Bueso-Ramos, Rashmi Kanagal-Shamanna, Keyur P. Patel and Hagop M. Kantarjian. A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). Blood 132, 2018.
Prajwal Boddu, Gautam Borthakur, Kiran Naqvi, William G. Wierda, Prithviraj Bose, Elias Jabbour, Zeev Estrov, Jan Andreas Burger, Yesid Alvarado, APRIL Deshmukh, Ami Patel, Antonio Cavazos, Lina Han, Hagop M. Kantarjian, Michael Andreeff, Marina Konopleva. Initial report of a phase I study of LY2510924 with idarubicin and cytarabine (IA) in relapsed/refractory (R/R) AML. J Clin Oncol 36(suppl), 2018. e-Pub 2018.
Gabriela Sanchez-Petitto, Guillermo Garcia-Manero, Nicholas James Short, Kiran Naqvi, Michael Andreeff, Koichi Takahashi, Steven Kornblau, Prithviraj Bose, Zeev Estrov, Marina Konopleva, Ami Patel, Rabiul Islam, Yesid Alvarado, Courtney Denton Dinardo, Hagop M. Kantarjian, Elias Jabbour. Omacetaxine mepesuccinate for patients with higher-risk MDS and CMML after failure of hypomethylating agents: A phase II clinical trial. J Clin Oncol 36(suppl), 2018. e-Pub 2018.
Boyu Hu, Keyur Patel, Hsiang-Chun Chen, Xuemei Wang, Rajyalakshmi Luthra, Mark Routbort, Rashmi Kanagal-Shamanna, L Jeffrey Medeiros, Cameron C. Yin, Zhuang Zuo, Chi Ok, Sanam Loghavi, Philip A. Thompson, Michael J. Keating, Jan Andreas Burger, Nitin Jain, Alessandra Ferrajoli, Prithviraj Bose, Zeev Estrov, William G. Wierda. Association of ATM mutation and unmutated IGHV status with shorter time to first treatment (TTFT): An analysis of multigene mutation profiling and standard prognostic clinical markers in 384 treatment-naive (TN) chronic lymphocytic leukemia (CLL). J Clin Oncol 36(suppl), 2018. e-Pub 2018.
Ahmad Ghorab, Hagop M. Kantarjian, Preetesh Jain, Rashmi Kanagal-Shamanna, Elias Jabbour, Koji Sasaki, Tapan M. Kadia, Guillermo Garcia-Manero, Prithviraj Bose, Musa Yilmaz, Kiran Naqvi, William G. Wierda, Srdan Verstovsek, Nitin Jain, Zeev Estrov, Farhad Ravandi, Susan Mary O'Brien, Jorge E. Cortes.. Concordant extra-medullary and bone marrow disease (EMD-BM) of blastic transformation of chronic myeloid leukemia (CML-BP) in the tyrosine kinase (TKI) era: Characteristics, treatments and outcomes. J Clin Oncol 36(suppl), 2018. e-Pub 2018.
Lucia Masarova, Srdan Verstovsek, Jorge Cortes, Naveen Pemmaraju, Elias Jabbour, Prithviraj Bose, Maro Ohanian, Lingsha Zhou, Sherry Pierce, Romany Gergis, Gautam Borthakur, Zeev Estrov, Guillermo Garcia-Manero, Hagop Kantarjian, Naval Daver.. PHASE 2 STUDY OF RUXOLITINIB IN COMBINATION WITH 5-AZACITIDINE IN PATIENTS WITH MYELOFIBROSIS. Haematologica, 2018. e-Pub 2018.
Guillermo Garcia-Manero, Prithviraj Bose, Yesid Alvarado, Gautam Borthakur, Naval Daver, Farhad Ravandi-Kashani, Elias Jabbour, Koichi Takahashi, Michael Andreeff, Tapan Kadia, Courtney DiNardo, Jorge Cortes, Steven Kornblau, Kiran Naqvi, Christopher Benton, Maro Ohanian, Marina Konopleva, Zeev Estrov, Guillermo Montalban-Bravo, Sherry Pierce, Kristy Bodden, Hagop Kantarjian.. A PHASE II CLINICAL TRIAL OF GUADECITABINE (SGI-110) FOR PATIENTS WITH PREVIOUSLY UNTREATED MYELODYSPLASTIC SYNDROME. Haematologica, 2018. e-Pub 2018.
Jain N, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Bose P, Estrov Z, Jabbour EJ, Konopleva M, Alvarado Y, Kadia T, Yilmaz M, DiNardo CD, Ohanian M, Cortes JE, Kanagal-Shamanna R, Patel K, Garg N, Wang X, Fru N, Cruz N, Gandhi V, Plunkett W, Kantarjian HM, Keating MJ, Wierda W. Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial. Blood, 2017.
Yilmaz M, Jabbour EJ, Wang X, Loghavi S, Khoury JD, Jorgensen JL, Ravandi F, Short NJ, Cortes JE, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Khouri M, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien SM, Kantarjian HM. Dynamics of Measurable Disease at Remission Determines Survival in Patients (pts) with Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (ALL). Blood, 2017.
Short NJ, Kantarjian HM, Garcia-Manero G, Borthakur G, Kadia T, Huang X, Daver N, DiNardo CD, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Bose P, Alvarado Y, Kornblau S, Ohanian M, Gasior Y, Richie MA, Pierce S, Jabbour EJ, Cortes JE, Ravandi F. A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia. Blood 130, 2017.
Yilmaz M, Kantarjian HM, Wang X, KC D, Khoury JD, Ravandi F, Short NJ, Cortes JE, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Wierda W, Khouri M, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien SM, Jabbour EJ. Prognostic Index for Survival in Adult Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia (ALL). Blood 130, 2017.
Maiti A, Kantarjian HM, Ravandi F, Khouri M, Thomas DA, Garcia-Manero G, Garris R, Cortes JE, Short NJ, Jain N, Bose P, Verstovsek S, Konopleva M, Sasaki K, Issa GC, Ghosn M, Schroeder HM, Kadia T, Daver N, O'Brien SM, Jabbour EJ. Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+ Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial. Blood 130, 2017.
Hu B, Patel K, Wang X, Chen H-C, Thompson PA, Keating MJ, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Luthra R, Routbort M, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Wierda WG. Standardized Targeted Sequencing of 29 Genes with Recurrent Mutations in Chronic Lymphocytic Leukemia (CLL) Helps to Better Define Clinical Correlates and Genomic Hotspots. Blood 130, 2017.
Assi R, Bose P, Verstovsek S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau S, Kadia T, Daver N, Brandt M, Pierce S, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial. Blood 130, 2017.
Jain N, Thompson PA, Burger JA, Borthakur G, Bose P, Estrov Z, Ferrajoli A, Takahashi K, Garg N, Wang X, Gandhi V, Plunkett W, Kanagal-Shamanna R, Patel K, Lopez W, Kantarjian HM, O'Brien SM, Keating MJ, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations. Blood 130, 2017.
Short NJ, Garcia-Manero G, Naqvi K, Kornblau S, Takahashi K, Montalban-Bravo G, Khouri R, Andreeff M, Konopleva M, DiNardo CD, Alvarado Y, Ghosn M, Estrov Z, Bose P, Islam R, Dong X, Cortes J, Kantarjian HM, Jabbour EJ. Omacetaxine Mepesuccinate for Patients with Higher-Risk MDS and CMML after Failure of Hypomethylating Agents: A Phase II Trial. Blood 130, 2017.
Ghorab A, Jain P, Kantarjian HM, Kanagal-Shamanna R, Jabbour EJ, Sasaki K, Kadia T, Garcia-Manero G, Bose P, Yilmaz M, Naqvi K, Wierda WG, Verstovsek S, Jain N, Estrov Z, Ravandi F, O'Brien SM, Cortes JE. Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes. Blood 130, 2017.
Pemmaraju N, Carter BZ, Kantarjian HM, Bose P, Kadia T, Jabbour EJ, DiNardo CD, Daver N, Estrov Z, Cortes JE, Garcia-Manero G, Zhou L, Mak PY, Salinas K, Tuttle CK, Pierce S, Popat U, Verstovsek S. Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis. Blood 130, 2017.
Bose P, Pemmaraju N, Schroeder K, Ferrajoli A, Jabbour EJ, Daver N, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Kantarjian HM, Verstovsek S. Phase 2 Study of Pracinostat in Combination with Ruxolitinib in Patients (pts) with Myelofibrosis (MF). Blood 130, 2017.
Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Pemmaraju N, KC D, Pierce S, Patel KP, Konopleva M, Ravandi F, Garcia-Manero G, Kadia T, Cortes JE, Kantarjian HM, Andreeff M, Verstovsek S. JAK2 Variants Associated with Secondary-AML from MPN. Blood 130, 2017.
Rozovski U, Harris DM, Li P, Liu Z, Manshouri T, Veletic I, Bueso-Ramos C, Jain P, Verstovsek S, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Keating MJ, Estrov Z. CLL Cell-Derived Exosomes Promote Bone Marrow Fibrosis and Inhibit Normal Hematopoietic Colony Proliferation. Blood 130, 2017.
Bose P, Daver N, Pemmaraju N, Jabbour EJ, Estrov Z, Pike A, Huynh-Lu J, Nguyen-Cao M, Wang X, Zhou L, Pierce S, Kantarjian HM, Verstovsek S. Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia. Blood 130, 2017.
Srour S, Desai P, Ciurea SO, Bashir Q, Oran B, Olson AL, Ahmed S, Bose P, Mehta RS, Pemmaraju N, Verstovsek S, Champlin RE, Popat U. Myeloid Mixed Chimerism and Relapse in Myelofibrosis after Allogeneic Stem Cell Transplant. Blood 130, 2017.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Keating MJ, Estrov Z. Overexpression of CD36, Driven By STAT3, Mediates Free Fatty Acid Uptake in CLL Cells. Blood 130, 2017.
Bose P, Chen L, Cruz N, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll M, Jain N, Wierda WG, Keating MJ, Gandhi V. A Pilot Study of Lower Doses of Ibrutinib in Patients (pts) with Chronic Lymphocytic Leukemia (CLL). Blood 130, 2017.
Naqvi K, Cortes JE, Skinner J, Jabbour EJ, Pemmaraju N, Bose P, Thompson PA, Borthakur G, Estrov Z, Kantarjian HM. Evaluating the Role of Lower Dose Dasatinib in Newly Diagnosed Early Chronic Phase-Chronic Myeloid Leukemia (CML-CP). Blood 130, 2017.
Boddu P, Mansurov A, Masarova L, Bose P, Patel KP, Estrov Z, Kantarjian HM, Verstovsek S. Non-Driver Mutations and Gene Sequence Variants Identified By Targeted Deep Sequencing in Polycythemia Vera and Essential Thrombocythemia. Blood 130, 2017.
Masarova L, Bose P, Pemmaraju N, Daver N, Cortes JE, Estrov Z, Kantarjian HM, Verstovsek S. Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center. Blood 130, 2017.
Masarova L, Bose P, Pemmaraju N, Daver N, Cortes JE, Estrov Z, Kantarjian HM, Verstovsek S. Characteristics and Survival of Patients with Chronic Phase Myelofibrosis and Elevated Blasts (5-9%), and the Effect of Therapy with JAK2 Inhibitor Ruxolitinib. Blood 130, 2017.
Falchi L, Chihara D, Bose P, Estrov Z, Kantarjian HM, Ravandi F, Verstovsek S. Myelofibrosis (MF) Leukemic Transformation (LT) in the Era of Ruxolitinib and Genomics: Characteristics and Outcomes. Blood 130, 2017.
Alhuraiji A, Naqvi K, Huh YO, Ho C, Verstovsek S, Bose P. JAK2 V617F Acute Lymphoblastic Leukemia Secondary to Myeloproliferative Neoplasms (MPNs) or After Lenalidomide Exposure: Case Report and Review of the Literature. Clin Lymphoma Myeloma Leuk 17(Suppl 2):S254, 2017.
Naqvi K, Cortes J, Skinner J, Jabbour E, Pemmaraju N, Borthakur G, Estrov Z, Bose P, Thompson P, Kantarjian H. Therapy with Lower Dose Dasatinib in Newly Diagnosed Early Chronic Phase-Chronic Myeloid Leukemia (CML-CP). Clin Lymphoma Myeloma Leuk 17(Suppl 2):S317, 2017.
Masarova L, Bose P, Abou Zahr A, Cortes J, Kantarjian H, Verstovsek S. Do We Need to Re-Define Accelerated Phase of Myelofibrosis? Correlation between Blast Percentage in Myelofibrosis and Outcomes. Clin Lymphoma Myeloma Leuk 17(Suppl 2):S352, 2017.
Masarova L, Bose P, Newberry K, Abou Zahr A, Cortes JE, Kantarjian HM, Verstovsek S.. Correlation between blast percentage in myelofibrosis and outcomes: a single-center experience. J Clin Oncol 35, 2017.
Bose P, Nazha A, Komrokji R, Savona M, Patel K, Pierce S, Al Ali N, Sochacki A, Shaver A, Daver N, DiNardo C, Garcia-Manero G, Bueso-Ramos C, Kantarjian H, Sekeres M, Maciejewski J, Verstovsek S. MUTATIONAL LANDSCAPE OF MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE NEOPLASM -. Haematologica (Roma) 102:118, 2017.
Naqvi K, Kadia T, Borthakur G, Takahashi K, Bose P, Daver N, Alvarado Y, Ohanian M, DiNardo C, Jabbour E, Garcia-Manero G, Kantarjian H, Patel A, Ravandi F. PHASE I/II STUDY OF MEK INHIBITOR (MEK-162; BINIMETINIB) IN PATIENTS WITH RELAPSED AND/OR. Haematologica (Roma) 102:375, 2017.
Garcia-Manero G, Daver N, Montalban-Bravo G, Jabbour E, DiNardo C, Kornblau S, Bose P, Alvarado Y, Ohanian M, Borthakur G, Cortes J, Naqvi K, Pemmaraju N, Huang X, Nogueras-Gonzalez G, Bueso-Ramos C, Gasior Y, Bayer V, Pierce S, Yang H, Colla S, Kantarjian H. AN UPDATE OF A PHASE II STUDY OF NIVOLUMAB (NIVO) OR IPILIMUMAB (IPI) WITH AZACITIDINE IN PTS WITH PREVIOUSLY TREATED OR UNTREATED MYELODYSPLASTIC SYNDROMES (MDS). Haematologica (Roma) 102:183, 2017.
Bose P, Daver N, Jabbour EJ, Pike A, Newberry KJ, Zhou L, Pierce S, Wang X, Kantarjian HM, Verstovsek S. Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia. Blood 128, 2016. e-Pub 2016.
Bose P, Verstovsek S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Brandt M, Pierce S, Nogueras-Gonzalez GM, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results. Blood 128, 2016. e-Pub 2016.
Benton CB, Takahashi K, Bose P, Wang F, Chen H-C, Zheng X, Zhang J, Wang X, Su X, Montalban-Bravo G, Issa G, Daver N, Jabbour E, DiNardo C, Bueso-Ramos C, Patel K, Kornblau S, Konopleva M, Borthakur G, Kadia T, Cortes J, Ravandi F, Andreeff M, Garcia-Manero G, Futreal A, Kantarjian H. Archetypes of AML defined using whole exome sequencing and clinical characteristics in a diverse group of patients. Blood 128, 2016. e-Pub 2016.
Masarova L, Popat U, Bose P Champlin R, Cortes J, Kantarjian H, Verstovsek S. Allogeneic stem cell transplantation versus medical therapy in patients with advanced myelofibrosis: matched survival analysis and the effect of JAK2 inhibitor therapy. Blood 128, 2016. e-Pub 2016.
Montalban-Bravo G, Bose P, Alvarado Y, Daver N, Ravandi F, Borthakur G, Takahashi K, Andreeff M, Cortes J, DiNardo C, Jabbour E, Kadia T, Kornblau S, Ohanian M, Alfonso A, Huang X, Nogueras-Gonzalez GM, Bodden K, Littles K, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Initial results of a Phase 2 Study of Guadecitabine (SGI-110), A Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood 128, 2016. e-Pub 2016.
Jain P, Wang S, Kantarjian H, Sarwari N, Patel KP, Bose P, Pierce S, Kadia TM, Daver N, Pemmaraju N, Cortes J, Verstovsek S. Aleukemic mast cell leukemia (aMCL) – clinical characteristics and outcomes. Blood 128, 2016. e-Pub 2016.
Abaza Y, Kantarjian H, Jabbour E, Thomas D, Kadia T, Borthakur G, Burger J, Wierda W, Jain N, Faderl S, O'Brien S, Konopleva M, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Bose P, Thompson P, Kelly M, Garris R, Garcia-Manero G, Cortes J, Ravandi F. Phase II Study of Hyper-CVAD plus Nelarabine in Previously Untreated Adult T-cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. Blood 128, 2016. e-Pub 2016.
Daver N, Cortes J, Pemmaraju N, Jabbour E, Bose P, Zhou L, Pierce S, Van Derbur S, Tuttle C, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian H, Verstovsek S. Ruxolitinib (RUX) in Combination with Azacytidine (AZA) in Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs). Blood 128, 2016. e-Pub 2016.
Daver N, Cortes J, Pemmaraju N, Jabbour E, Bose P, Zhou L, Pierce S, Van Derbur S, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian H, Verstovsek S. Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) as Therapy for Patients (pts) with Myelofibrosis (MF). Blood 128, 2016. e-Pub 2016.
Khan M, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, Huang X, Daver N, DiNardo C, Ferrajoli A, Wierda WG, Estrov Z, Benton CB, Bose P, Alvarado Y, Kornblau SM, Ohanian M, Gasior Y, Richie MA, Pierce S, Jabbour E, Cortes JE, Ravandi F. Randomized Phase II Trial of Two Schedules of Decitabine as Frontline Therapy in Elderly Patients with Acute Myeloid Leukemia Ineligible for Standard Cytotoxic Induction Regimens. Blood 128, 2016. e-Pub 2016.
Short NJ, Garcia-Manero G, Naqvi K, Kornblau S, Maiti A, Konopleva M, DiNardo C, Takahashi K, Alvarado Y, Ohanian M, Estrov Z, Bose P, Andreeff M, Islam R, Dong XQ, Cortes J, Kantarjian H, Jabbour E. A Phase II Trial of Omacetaxine Mepesuccinate for Patients with High-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agents. Blood 128, 2016. e-Pub 2016.
Sasaki K, Kantarjian H, Ravandi F, Daver N, Kadia T, Khouri RB, Alvarado Y, Burger J, Thomas D, Garcia-Manero G, DiNardo C, Pemmaraju N, Garris R, Schroeder H, Bose P, Jain N, Naqvi K, Wierda W, Verstovsek S, Cortes J, Konopleva M, O'Brien S, Jabbour E. Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood 128, 2016. e-Pub 2016.
Pemmaraju N, Carter BZ, Kantarjian H, Cortes J, Kadia T, Garcia-Manero G, DiNardo C, Bose P, Pierce S, Zhou L, Estrov Z, Tuttle C, Salinas K, Mak PY, Verstovsek S. Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF). Blood 128, 2016. e-Pub 2016.
Sasaki K, Jabbour E, O'Brien S, Thomas D, Ravandi F, Garcia-Manero G, Cortes J, Short N, Verstovsek S, Yilmaz M, Wierda W, Borthakur G, Kadia T, Konopleva M, Khouri M, Ferrajoli A, Daver N, Pemmaraju N, DiNardo C, Jain N, Benton C, Takahashi K, Naqvi K, Bose P, Kornblau S, Andreeff M, Keating M, Freireich E, Kantarjian H. Outcome of Patients with Acute Lymphoblastic Leukemia (ALL) by Age Group over 35 Years: A Single Institution Experience. Blood 128, 2016. e-Pub 2016.
Short NJ, Jabbour E, Sasaki K, Ko H, Ravandi F, Yin C, Khouri MR, Cortes JE, Garris R, O'Brien SM, Patel K, Garcia-Manero G, Thomas D, Daver N, Naqvi K, Bose P, Jain N, Konopleva M, Kantarjian H. Additional Chromosomal Abnormalities in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors: Differential Outcomes According to Type of Chromosomal Abnormality. Blood 128, 2016. e-Pub 2016.
Ohanian M, Kantarjian H, Borthakur G, Kadia TM, Konopleva M, Garcia-Manero G, Estrov Z, Ferrajoli A, Takahashi K, Jabbour EJ, Daver N, Kornblau SM, Wierda WG, Burger JA, Naqvi K, Benton CB, Bose P, Eckardt J, Ravandi F, Cortes JE. Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-dose Ara-C in Multiply Relapsed/ Refractory FLT3+ AML. Blood 128, 2016. e-Pub 2016.
Garcia-Manero G, Daver NG, Montalban-Bravo G, Jabbour EJ, DiNardo CD, Kornblau SM, Bose P, Alvarado Y, Ohanian M, Borthakur G, Cortes JE, Naqvi K, Pemmaraju N, Huang X, Nogueras-Gonzalez GM, Bueso-Ramos CE, Gasior Y, Bayer VR, Pierce S, Yang H, Colla S, Kantarjian HM. A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS). Blood 128, 2016. e-Pub 2016.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, O'Brien SM, Bose P, Thompson PA, Jain N, Wierda WG, Keating M, Estrov Z. Ibrutinib Disrupts the Metabolic Program of CLL Cells in-Vivo. Blood 128, 2016. e-Pub 2016.
Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, O'Brien SM, Bose P, Thompson PA, Jain N, Wierda W, Keating M, Estrov Z. Casein Kinase-2 Induces Constitutive Phosphorylation of STAT3 in CLL Cells. Blood 128, 2016. e-Pub 2016.
Strati P, Bose P, Gaw K, Zhou L, Pierce S, Huynh-Lu J, Bueso-Ramos CE, Verstovsek S. Immature Platelet Fraction Is Associated with JAK2 V617F Mutation and Features of Advanced Disease in Myelofibrosis. Blood 128, 2016. e-Pub 2016.
Chihara D, Kantarjian HM, Newberry KJ, Ravandi F, Daver NG, Bose P, DiNardo CD, Pemmaraju N, Kadia TM, Borthakur G, Konopleva M, Garcia-Manero G, Popat UR, Cortes JE, Verstovsek S. Survival Outcome of Patients with Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms. Blood 128, 2016. e-Pub 2016.
Masarova L, Bose P, Daver N, Newberry KJ, Cortes JE, Garcia-Manero G, Kantarjian HM, Verstovsek S. Clinical characteristics of patients with primary or post-polycythemia vera/post-essential thrombocythemia myelofibrosis and deletion 13q. Clin Lymphoma Myeloma Leuk 16(S2), 2016.
Masarova L, Bose P, Newberry KJ, Cortes JE, Garcia-Manero G, Kantarjian HM, Verstovsek S. Therapy-Related Myelofibrosis does not appear to exist. Clin Lymphoma Myeloma Leuk 16(S2), 2016.
Masarova L, Bose P, Pemmaraju N, Daver NG, Newberry K, Cortes JE, Kantarjian HM, Verstovsek S. Does therapy-related myelofibrosis exist? Analysis of 1100 myelofibrosis cases from a single institution. J Clin Oncol 34, 2016.
Alhuraiji A, Masarova L, Bose P, Daver NG, Cortes JE, Pierce S, Kantarjian HM, Verstovsek S. Clinical features and outcome of patients with poor-prognosis myelofibrosis based on platelet count <50 x 109/L: A single-center experience in 1100 myelofibrosis patients. J Clin Oncol 34, 2016.
Yilmaz M, Kantarjian HM, Cortes J, Garcia-Manero G, Chahoud J, Ravandi F, Sasaki K, Takahashi K, Wierda WG, Jain N, Verstovsek S, Estrov Z, Bose P Pierce S, Jabbour E.. Results of Intensive Chemotherapy in 434 Adult Patients (pts) with Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL): Predictive Prognostic Model for Survival. Blood 126(23), 2015.
Kadia T, Cortes JE, Ravandi F, Garcia-Manero G, Andreeff M, Takahashi K, Borthakur G, Jabbour EJ, Bhalla KN, Konopleva M, Daver N, DiNardo C, Bose P, Patel KP, Pierce S, Kantarjian HM.. Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia. Blood 126(23), 2015.
Jain PL, Sasaki K, Kantarjian H, Ravandi F, Cortes JE, Garcia-Manero G, Bose P, Daver N, Kadia T, Verstovsek S, Konopleva M, Jain N, Bravo Montalban G, Pierce S, Jabbour E.. Outcome of Adult Patients with Philadelphia Negative B Cell Acute Lymphoblastic Leukemia after Frontline Therapy Failure. Blood 126(23), 2015.
KC B, Kantarjian HM, Garcia-Manero G, Daver N, Borthakur G, Konopleva M, Andreeff M, Chihara D, Kadia T, Bose P, Estrov Z, Pemmaraju N, Ravandi F, Cortes JE.. Prognostic Significance of Somatic Mutations in Treatment of AML in Salvage Setting: A Retrospective Analysis. Blood 126(23), 2015.
Masarova L, Daver N, Pemmaraju N, Bose P, Pierce S, Manshouri T, Cortes JE, Kantarjian HM, Verstovsek S.. Do Patients with Post-Essential Thrombocythemia and post-Polycthemia Vera Differ from Patients with Primary Myelofibrosis?. Blood 126(23), 2015.
Beata Holkova, Maciej Kmieciak, Prithviraj Bose, Shuo Ma, Amy Kimball, Mary Beth Tombes, Ellen Shrader, Wen Wan, Caryn Weir-Wiggins, Elizabeth Stoddert, Amanda Garnett Singh, April Dean, Sarah Conine, Heidi Sankala, John D. Roberts, Thomas C. Shea & Steven Grant.. Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results. Blood 124(21), 2014.
Joshua F. Zeidner, Matthew C. Foster, Amanda Blackford, Mark R. Litzow, Lawrence E. Morris, Stephen A. Strickland, Jeffrey E. Lancet, Prithviraj Bose, Yair Levy, Raoul Tibes, Ivana Gojo, Chistopher D. Gocke, Jacqueline M. Greer, Joan M. Cain, Richard F. Little, John J. Wright, L. Austin Doyle, B. Douglas Smith & Judith E. Karp.. Randomized multicenter phase II trial of timed-sequential therapy with flavopiridol (alvocidib), cytarabine and mitoxantrone (FLAM) versus “7+3” for adults with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol 32, 2014.
Beata Holkova, Maciej Kmieciak, Prithviraj Bose, Paul M. Barr, Mary Beth Tombes, Ellen Shrader, Erin Cebula, Emily Pierce, Megan M. Herr, Heidi Sankala, Changyong Feng, Richard I. Fisher, Steven Grant, Jonathan W. Friedberg.. Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas. Blood 122, 2013.
Joshua F. Zeidner, Jonathan M. Gerber, Amanda Blackford, Mark Litzow, Matthew Foster, Lawrence Morris, Ivana Gojo, Jeffrey Lancet, Prithviraj Bose, Raoul Tibes, Stephen Strickland, Jacqueline Greer, Michelle Drye, Kevin Meads, L. Austin Doyle, Richard F. Little, John J. Wright & Judith E Karp.. Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus "7+3" for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 120(21), 2012.
Beata Holkova, Thomas C. Shea, Prithviraj Bose, Mary Beth Tombes, Ellen Shrader, Wen Wan, Caryn Weir-Wiggins, Elizabeth Stoddert, Heidi Sankala, Maciej Kmieciak, John D. Roberts, Steven Grant.. Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma. Blood 120(21), 2012.
Beata Holkova, Prithviraj Bose, Mary Beth Tombes, Ellen Shrader, Wen Wan, Caryn Weir-Wiggins, Elizabeth Stoddert, Heidi Sankala, Maciej Kmieciak, John D. Roberts, Guillermo Garcia-Manero, Steven Grant.. Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis – One Year Update. Blood 120(21), 2012.
Beata Holkova, E. Brent Perkins, Prithviraj Bose, Daniel Sullivan, Rachid C. Baz, Mary Beth Tombes, Ellen Shrader, Viswanathan Ramakrishnan, Wen Wan, Heidi Sankala, Maciej Kmieciak, John D. Roberts, Steven Grant.. Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms – Update of the “Bolus” Infusion Schedule of Alvocidib. Blood 120(21), 2012.
Li J, Gatesman ML, Newland AM, Sabo R, Bose P.. FLAG ± Idarubicin Compared with 7+3 As Initial Induction for Secondary Acute Myeloid Leukemia: A Single Institution Experience. Blood 120(21), 2012.
Bose P, Holter JL, Selby GB.. Use of Bevacizumab in Hereditary Hemorrhagic Telangiectasia. Blood 112(11):1338, 2008.
Bose P, Nakadar S, Ali AY, Reyes MP.. Daptomycin-induced rhabdomyolysis. J Gen Int Med 22(S1):240, 2007.
Bose P, Al-Romaihi D, Movva K.. Hypokalemic periodic paralysis: Not always familial. J Gen Int Med 22(S1):211, 2007.
Bose P, Shah V.. Clinically confirmed Heparin Induced Thrombocytopenia (HIT) presenting with Unusually Low Platelet Count and Negative HIT Antibodies. J Gen Int Med 21(S4):231, 2006.
Bose P, Thompson JA.. Fatal HHV-6 Encephalitis following treatment of High Grade T Cell Non Hodgkin Lymphoma with Autologous Stem Cell Transplantation and Campath. J Gen Int Med 21(S4):237, 2006.
Masarova L, Bose P, Daver N, Pemmaraju N, Newberry K, Cortes J, Kantarjian H, Verstovsek S. Cytogenetic risk stratification in primary versus post-essential thrombocythemia / post-polycythemia vera myelofibrosis. Blood 128. e-Pub 2016.
Masarova L, Cortes JE, Pemmaraju N, Jabbour E, Bose P, Ohanian M, Zhou L, Pierce S, Gergis R, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian HM, Verstovsek S, Daver NG.. Phase 2 study of Ruxolitinib in combination with 5-azacitidine in patients with myelofibrosis. J Clin Oncol 35. e-Pub 2017.
Montalban-Bravo G, Bose P, Alvarado Y, Daver NG, Ravandi F, Borthakur G, Takahashi K, Andreeff M, Cortes JE, DiNardo CD, Jabbour E, Kadia TM, Kornblau S, Ohanian M, Huang X, Nogueras-Gonzalez GM, Bodden K, Pierce S, Kantarjian HM, Garcia-Manero G.. Updated results from Phase 2 Study of Guadecitabine for Patients with Higher Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia. J Clin Oncol 35. e-Pub 2017.
Assi R, Cortes JE, Pemmaraju N, Jabbour E, Bose P, Kadia TM, DiNardo CD, Zhou L, Pierce S, Van Derbur S, Tuttle C, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian HM, Verstovsek S, Daver NG.. Ruxolitinib (RUX) in Combination with Azacytidine (AZA) in Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs). J Clin Oncol 35. e-Pub 2017.
Boddu P, Jorgensen JL, Kantarjian HM, Borthakur G, Kadia TM, Daver NG, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour E, Garcia-Manero G, Cortes JE, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces risk of relapse. J Clin Oncol 35. e-Pub 2017.
Jain N, Thompson PA, Burger JA, Borthakur G, Bose P, Estrov Z, Ferrajoli A, Gandhi V, Plunkett W, Lopez W, Kantarjian HM, O’Brien SM, Keating MJ, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) with Mutated IGHV and Non-del(17p). J Clin Oncol 35. e-Pub 2017.
Naqvi K, Cortes JE, Skinner JA, Jabbour E, Pemmaraju N, Borthakur G, Estrov Z, Bose P, Thompson PA, Kantarjian HM.. Early Results of Lower Dose Dasatinib, 50mg Daily, in Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase. J Clin Oncol 35. e-Pub 2017.

Book Chapters

Bose P, Verstovsek S. Polycythemia Vera. In: BMJ Best Practice. BMJ Publishing Group Limited: United Kingdom, 2018.
Bose P, Verstovsek S. Polycythemia vera. In: BMJ Best Practice, 2016.
Bose P, Grant S.. Bcl-2 family: translational aspects. In: Targeted Therapy of Acute Myeloid Leukemia. Springer: New York, 67-94, 2015.
Dai Y, Bose P, Grant S.. Cell cycle regulation and hematologic disorders. In: Williams Hematology. 9. Mc-Graw Hill: New York, 2015.
Bose P, Vachhani P.. Can we cure CML without transplantation?. In: Chronic Myeloid Leukemia: From Daily Management to Complicated Issues. Nova: New York, 279-326, 2014.
Ustun C, Warlick E, Bose P, Radich JP, Goldman JM.. Summary of treatment and recommended follow-up of CML patients. In: Chronic Myeloid Leukemia: From Daily Management to Complicated Issues. Nova: New York, 183-190, 2014.
Batalo MS, Bose P, Holkova B, Grant S.. Targeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition. In: Resistance to Proteasome Inhibitors in Cancer. Springer: Switzerland, 149-179, 2014.
Poklepovic A, Bose P. Molecularly Targeted Therapy: Imatinib and Beyond. In: Gastrointestinal Stromal Tumor. InTech: Croatia, 47-60, 2012.
Park H, Poklepovic A, Bose P.. Emerging therapeutic options for metastatic exocrine pancreatic cancer. In: Pancreas: Anatomy, Diseases and Health Implications. Nova: New York, 159-172, 2012.

Letters to the Editor

Bose P, Holter JL, Selby GB.. More on Bevacizumab in Hereditary Hemorrhagic Telangiectasia (author reply). N Engl J Med 361: 931-932, 2009.

Less

Grant & Contract Support

Title:	Alternating or Combined Therapy with Axitinib and Bosutinib for Patients with Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases
Funding Source:	Pfizer
Role:	Principal Investigator

Title:	A Phase 1 Study of BLU-285 in Patients with Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies
Funding Source:	Blueprint Medicines Corporation
Role:	Principal Investigator

Title:	A Phase II study of isavuconazole prophylaxis in adult patients with AML/MDS and neutropenia
Funding Source:	Astellas Pharma
Role:	Principal Investigator

Title:	A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects with Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea
Funding Source:	Incyte Corporation
Role:	Principal Investigator

Title:	An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib
Funding Source:	CTI BioPharma
Role:	Principal Investigator

Title:	EVALUATION OF RUXOLITINIB and THALIDOMIDE COMBINATION AS A THERAPY FOR PATIENTS WITH MYELOFIBROSIS
Funding Source:	Memorial Sloan Kettering Cancer Center
Role:	Principal Investigator

Title:	A phase 2, multicenter, open-label study to evaluate the efficacy and safety of luspatercept (ACE-536) in subjects with myeloproliferative neoplasm-associated myelofibrosis and anemia with and without red blood cell-transfusion dependence
Funding Source:	Celgene Corporation
Role:	Principal Investigator

Title:	An Open-Label, Multi-center, Rollover Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Funding Source:	Incyte Corporation
Role:	Principal Investigator

Title:	A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)
Funding Source:	Constellation Pharmaceuticals, Inc
Role:	Principal Investigator

Title:	An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis
Funding Source:	Blueprint Medicines
Role:	Principal Investigator

Title:	An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor
Funding Source:	Kartos Therapeutics
Role:	Principal Investigator

Title:	A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera
Funding Source:	Kartos Therapeutics
Role:	Principal Investigator

Title:	A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)
Funding Source:	Promedior
Role:	Principal Investigator

Prithviraj Bose, M.D.

About Dr. Bose

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Honors & Awards

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Grant & Contract Support

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Prithviraj Bose, M.D.

About Dr. Bose

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Honors & Awards

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Grant & Contract Support

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Give Now

Donate Blood

Volunteer